Welcome to the IMPACCT Real World Evidence Summit West
Is your organization ready to lead the next era of evidence generation?
With CMS rolling out new guidance for real-world data studies and the FDA launching its Center for RWE Innovation, the message is clear: real-world evidence is no longer optional it's essential. As data becomes more accessible and advanced analytics unlock deeper insights, investment in RWE is accelerating at an unprecedented pace.
The West Coast is filled with forward-thinking pharma and biotech companies are harnessing AI, digital health, and real-world data to uncover unmet needs, demonstrate treatment value beyond the clinical trial setting, and influence decision-making across regulators, payers, providers, and patients.
Are you keeping up or leading the change?
Join the RWE leaders shaping this movement at the IMPACCT Real World Evidence Summit West and discover how to transform data into decisions across the entire product lifecycle.
What is best practice in selecting the right datasets and how can data quality be trusted? What are regulators and payers actually looking for as supporting evidence? How can integrated evidence generation plans be streamlined across functions?
Following the successful Boston and European meetings, the IMPACCT Real World Evidence Summit West is uniting RWE experts across Clinical Development, Value & Access, HEOR, and Commercial teams to consolidate, innovate and apply RWE across the drug development lifecycle, from external control arms to reimbursement.
Your Expert Speaker Faculty
Shaun Rowark
Associate Director - Data Access & Analysis
National Institute for Health & Clinical Excellence – NICE
Access the Full Agenda
• Uncover what constitutes ‘fit-for-purpose’ evidence from a payer and HTA body perspective.
• Enhance the predictive value of real-world studies through deeper biological context and mechanistic understanding.
• Balancing nuance and clarity while ensuring analytical complexity and audience accessibility is preserved.
• Takeaways from industry strategies to move from reactive fixes to proactive data governance and quality-by-design approaches.
What Your Peers Thought at Our Flagship:
"The interaction with RWE experts from other pharma companies and vendors was valuable. The content was extremely enriching"
Past Attendee, Senior Director, Real-World Evidence, Pfizer
"State-of-the art presentations addressing challenges anyone working in the health data space and evidence generation will be facing. A great forum to discuss methodologies and innovations to drive this community forward"
Past Attendee, Director, Value & Access, Eli Lilly & Co
"Very professional and knowledgeable speakers across both RWE clinical research and value and access"
Past Attendee, Head of Strategy, Johnson & Johnson
"Diversified knowledge and rich experience of the speakers made the event very enjoyable and educational "
Past Speaker, Senior Director, Chiesi
"Presentations from various expert stakeholders, small group discussions and networking sessions"
Past Speaker, Executive Director, HEOR, Pfizer
